Endra Life Sciences Inc. (NDRA) Stock Price & Analysis
Endra Life Sciences Inc. (NDRA) rose 3.51% to USD 4.42 as of June 10, 2026 at 03:46 UTC, according to Nexqual real-time market data.
NDRA last closed at USD 4.27; the session ranged USD 4.25–4.47 on volume of 18,255 shares. Market capitalization is $8.17M, with a 52-week range of USD 2.96–11.96 (NCM). Source: Nexqual, June 10, 2026 at 03:46 UTC.
Key Statistics (as of June 10, 2026 at 03:46 UTC)
| Price | USD 4.42 |
|---|---|
| Change | ▲ 3.51% (up) |
| Previous Close | USD 4.27 |
| Open | USD 4.47 |
| Day Range | USD 4.25 – 4.47 |
| 52-Week Range | USD 2.96 – 11.96 |
| Volume | 18,255 shares |
| Market Cap | $8.17M |
| Exchange | NCM |
Technical Analysis (NDRA)
Nexqual's technical model rates NDRA "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.56 (neutral) |
| vs SMA50 | Below (USD 5.11) |
| MACD | -0.16 (negative) |
Analyst Ratings (NDRA)
Wall Street analysts rate NDRA "Strong Buy" based on 1 analysts, with a mean price target of USD 25 (range USD 25–25), per Nexqual as of June 10, 2026 at 03:46 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 25 |
| High Target | USD 25 |
| Low Target | USD 25 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (NDRA)
| EPS Estimate | USD -0.84 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.09 vs est -1.23 ▲ beat |
| 2025-12-31 | USD -2.23 vs est -1.23 ▼ miss |
| 2025-09-30 | USD -2.1 vs est -1.95 ▼ miss |
| 2025-06-30 | USD -1.71 vs est -2.27 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
Financials & Fundamentals (NDRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -412.60% |
| Debt / Equity | 25.81 |
| Current Ratio | 0.64 |
| Total Cash | $356,462 |
| Total Debt | $461,206 |
| Free Cash Flow | $-5.91M |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
Financial Health Score (NDRA)
Nexqual rates Endra Life Sciences Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $356K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$5M |
| Efficiency | Critical — ROE -413%, ROA -122.3% |
Ownership (NDRA)
| Insider Ownership | +9.76% |
|---|---|
| Institutional Ownership | +11.13% |
| Shares Outstanding | 1.85M |
| Float | 1.20M |
| Short % of Float | +1.65% |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
Leadership (NDRA)
Endra Life Sciences Inc. is led by Alexander Y. Tokman (age 63), CEO & Chairman, per Nexqual as of June 10, 2026 at 03:46 UTC.
| CEO & Chairman | Alexander Y. Tokman (age 63) |
|---|---|
| CFO & Secretary | Richard Jacroux (age 57) |
Major Backers & Investors (NDRA)
Notable institutional backers of Endra Life Sciences Inc. include Altium Capital Management, LLC, Fidelity, Morgan Stanley, according to Nexqual as of June 10, 2026 at 03:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Altium Capital Management, LLC | 4.09% |
| Fidelity | 1.37% |
| Morgan Stanley | 0.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.66% |
| Vanguard Group | 1.24% |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
From Endra Life Sciences Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- The collection and use of health data and other personal data including data collected in clinical trials is governed in the EU by the General Data Protection Regulation ("GDPR"), which imposes substantial obligations upon companies and new rights for individuals.
- Before and after approval, grant or clearance in the United States, our applications are subject to extensive regulation by the FDA under the Federal Food, Drug and Cosmetic Act (the "FD&C Act") and/or the Public Health Service Act, as well as by other regulatory bodies.
- We also enter into nondisclosure agreements with our commercial counterparties and limit access to, and distribution of, our proprietary information.   We are committed to developing and protecting our intellectual property and, where appropriate, filing patent applications to protect our technology.
- These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images (and other forms of data) using our proprietary algorithms.
Partnerships
- In connection with its DAT strategy, Company entered into a Master Custody Service Agreement with Anchorage (the "Custody Agreement"), pursuant to which it will act as custodian of the Company's digital assets it deposits with Anchorage.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DARE | Dare Bioscience, Inc. | USD 1.92 | ▲ 2.13% |
| MOTS | Motus GI Holdings, Inc. | USD 0 | ▲ 0% |
| MBIO | Mustang Bio, Inc. | USD 0.74 | ▲ 10.75% |
| MBAI | Check-Cap Ltd. | USD 1.4 | ▲ 1.45% |
| DCOY | Decoy Therapeutics Inc. | USD 5.51 | ▼ 16.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:46 UTC. This page is informational and not investment advice.